About AVT
Browse Articles
Customer Services

Original article

Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment

Samantha Abel, John D Davis, Caroline E Ridgway, Julia C Hamlin, Manoli Vourvahis

Corresponding author name: Manoli Vourvahis
Corresponding author e-mail: manoli.vourvahis@pfizer.com

Citation: Antiviral Therapy 2009; 14:831-837
doi: 10.3851/IMP1297

Date accepted: 25 May 2009
Date published online: 05 October 2009


Background: Maraviroc is the first CCR5 antagonist and only oral entry inhibitor approved for the treatment of HIV type-1 infection. Maraviroc is extensively metabolized, primarily by cytochrome P450 3A4 and hence its pharmacokinetics might be affected by impaired hepatic function. The objective of this study was to evaluate the pharmacokinetics of maraviroc in subjects with mild or moderate hepatic impairment compared with subjects with normal hepatic function. Safety and tolerability were also assessed.

Methods: This was an open-label, non-randomized, single-centre, parallel-group study. A total of 24 subjects with mild (n=8) or moderate (n=8) hepatic impairment, or normal hepatic function (n=8) received a single dose of 300 mg maraviroc.

Results: Relative to those with normal hepatic function, the geometric mean ratio (90% confidence interval) for the maximum observed plasma concentration (Cmax) of maraviroc was 111% (74.6–166) and 132% (89.6–194) for those with mild and moderate hepatic impairment, respectively; the area under the concentration–time curve from time 0 to the last quantifiable concentration (AUClast) was 125% (84.7–185) and 146% (100–x200A;212); oral clearance was 89% (53.2–150) and 83% (49.2–x200A;139); and renal clearance was 94% (70.5–x200A;126) and 131% (98.6–173), respectively. Maraviroc was well tolerated in all subjects.

Conclusions: Although differences in maraviroc pharmacokinetics were noted in subjects with hepatic impairment compared with those with normal hepatic function, these do not currently support a dose modification. The single 300 mg dose of maraviroc was well tolerated by subjects with normal and impaired hepatic function.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.